XERS - ゼリス・ファ―マシュ―ティカルズ (Xeris Pharmaceuticals Inc.) ゼリス・ファ―マシュ―ティカルズ

 XERSのチャート


 XERSの企業情報

symbol XERS
会社名 Xeris Pharmaceuticals Inc (ゼリス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Xeris Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing injectable and infusible drug formulations. It uses its non-aqueous formulation technology platforms XeriSol and XeriJect to develop and commercialize its products. Its formulation technologies allow for the subcutaneous (SC) and intramuscular (IM) delivery of formulations of peptides proteins antibodies and small molecules using commercially-available syringes auto-injectors multi-dose pens and infusion pumps. The Company is developing its lead product candidate the Glucagon Rescue Pen for the treatment of severe hypoglycemia in people with diabetes. It is also developing treatments for post-bariatric hypoglycemia congenital hyperinsulinism hypoglycemia-associated autonomic failure and exercise-induced hypoglycemia. Its Glucagon Rescue Pen offers a stable glucagon that is designed to be administered subcutaneously in a simple two-step process.   ゼリス・ファ―マシュ―ティカルズは米国の特殊医薬品企業。疾患に対して、直ちに注射可能または注入可能な医薬品の開発・商品化に従事する。患者の皮下および筋肉内送達ができるペン型注射や注入ポンプに使用されるペプチド、タンパク質、抗体および小分子の製剤を開発する。同社リ―ド製品候補は糖尿病患者の低血糖を治療する。本社所在地はイリノイ州シカゴ。   Xeris Pharmaceuticals Inc. is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.
本社所在地 180 North LaSalle Street Suite 1810 Chicago IL 60601 USA
代表者氏名 Paul R. Edick ポールRエディック
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 512-498-2670
設立年月日 2005年
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数
url www.xerispharma.com
nasdaq_url https://www.nasdaq.com/symbol/xers
adr_tso
EBITDA EBITDA(百万ドル) -40.62100
終値(lastsale) 19.82
時価総額(marketcap) 412599143.66
時価総額 時価総額(百万ドル) 385.32850
売上高 売上高(百万ドル) 1.71900
企業価値(EV) 企業価値(EV)(百万ドル) 268.96750
当期純利益 当期純利益(百万ドル) -41.56700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Xeris Pharmaceuticals Inc revenues increased 18% to $1.1M. Net loss increased from $9.9M to $24.9M. Revenues reflect Grant income increase of 14% to $1M Service revenue increase from $16K to $53K. Higher net loss reflects Research and develop increase from $7.8M to $17.1M (expense) General and administrative - increase from $2.7M to $7.4M (expense) Interest expense increase from $1K to $753K (expense).

 XERSのテクニカル分析


 XERSのニュース

   Volatile Stock to Watch: Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), The Williams Companies, Inc. (NYSE:WMB)  2021/06/17 23:07:46 Stock Equity
Xeris Pharmaceuticals, Inc. (XERS) with the stream of -2.64% also noticed, India The Williams Companies, Inc. (WMB) encountered a rapid change of -2.18% in the last hour of Thursdays trading The post Volatile Stock to Watch: Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), The Williams Companies, Inc. (NYSE:WMB) appeared first on Stocks Equity .
   Xeris Pharmaceuticals Stock Is Estimated To Be Possible Value Trap  2021/06/10 19:00:19 GuruFocus
Related Stocks: XERS ,
   Xeris Pharmaceuticals Inc Shares Close the Week 29.8% Higher - Weekly Wrap  2021/06/04 22:30:00 Kwhen Finance
Xeris Pharmaceuticals Inc (XERS) shares closed this week 29.8% higher than it did at the end of last week. The stock is currently down 17.7% year-to-date, down 16.2% over the past 12 months, and down 80.0% over the past five years. This week, the Dow Jones Industrial Average rose 0.7%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $4.40 and as low as $2.94 this week.Trading volume this week was 70.1% higher than the 10-day average and 310.6% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -33.8% The company's stock price performance over the past 12 months beats the peer average by -6.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Mizuho Securities Sticks to Their Buy Rating for Xeris Pharmaceuticals (XERS)  2021/06/04 12:36:05 Smarter Analyst
Mizuho Securities analyst Difei Yang maintained a Buy rating on Xeris Pharmaceuticals (XERS) today and set a price target of $9.00. The post Mizuho Securities Sticks to Their Buy Rating for Xeris Pharmaceuticals (XERS) appeared first on Smarter Analyst .
   Form 8.3 -Xeris Pharmaceuticals Inc  2021/05/31 14:12:00 GlobeNewswire
FORM 8.3
   Xeris Pharmaceuticals Announces Pricing of $27.0 Million Registered Direct Offering  2021/03/11 12:00:00 Business Wire
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced the pricing of a registered direct offering of 6,553,398 shares of common stock, par value $0.0001 per share (the “Shares”), to funds managed by Deerfield Management Company, L.P., which are existing investors in the Company, at a purchas
   Xeris Pharmaceuticals Receives European Commission Approval of Ogluo™ (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus  2021/02/12 08:00:00 Business Wire
CHICAGO & DUBLIN--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the European Commission (EC) has approved Ogluo™ (glucagon) injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The marketing authorisation i
   Xeris Pharmaceuticals: Q3 Earnings Insights  2020/11/09 07:28:00 Benzinga
Shares of Xeris Pharmaceuticals (NASDAQ:XERS) moved higher by 4.6% in pre-market trading after the company reported Q3 results. Quarterly …
   Xeris Pharmaceuticals Inc (NASDAQ:XERS) to Post Q3 2020 Earnings of ($0.55) Per Share, SVB Leerink Forecasts  2020/10/22 07:50:57 Dispatch Tribunal
Xeris Pharmaceuticals Inc (NASDAQ:XERS) – Analysts at SVB Leerink cut their Q3 2020 earnings estimates for Xeris Pharmaceuticals in a research report issued to clients and investors on Tuesday, October 20th. SVB Leerink analyst A. Fadia now expects that the company will earn ($0.55) per share for the quarter, down from their previous estimate of […]
   Are Options Traders Betting on a Big Move in Xeris Pharmaceuticals (XERS) Stock?  2020/08/18 12:57:12 Yahoo Finance
Investors need to pay close attention to Xeris Pharmaceuticals (XERS) stock based on the movements in the options market lately.
   Xeris Pharmaceuticals Receives European Commission Approval of Ogluo™ (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus  2021/02/12 08:00:00 Business Wire
CHICAGO & DUBLIN--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the European Commission (EC) has approved Ogluo™ (glucagon) injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The marketing authorisation i
   Xeris Pharmaceuticals: Q3 Earnings Insights  2020/11/09 07:28:00 Benzinga
Shares of Xeris Pharmaceuticals (NASDAQ:XERS) moved higher by 4.6% in pre-market trading after the company reported Q3 results. Quarterly …
   Xeris Pharmaceuticals Inc (NASDAQ:XERS) to Post Q3 2020 Earnings of ($0.55) Per Share, SVB Leerink Forecasts  2020/10/22 07:50:57 Dispatch Tribunal
Xeris Pharmaceuticals Inc (NASDAQ:XERS) – Analysts at SVB Leerink cut their Q3 2020 earnings estimates for Xeris Pharmaceuticals in a research report issued to clients and investors on Tuesday, October 20th. SVB Leerink analyst A. Fadia now expects that the company will earn ($0.55) per share for the quarter, down from their previous estimate of […]
   Are Options Traders Betting on a Big Move in Xeris Pharmaceuticals (XERS) Stock?  2020/08/18 12:57:12 Yahoo Finance
Investors need to pay close attention to Xeris Pharmaceuticals (XERS) stock based on the movements in the options market lately.
   Earnings Scheduled For August 10, 2020  2020/08/10 08:10:24 Benzinga
Companies Reporting Before The Bell • Acacia Research Inc. (NASDAQ: ACTG ) is expected to report quarterly loss at $0.02 per share on revenue of $200.00 thousand. • Akebia Therapeutics Inc. (NASDAQ: AKBA ) is expected to report quarterly loss at $0.50 per share on revenue of $74.18 million. • Apyx Medical Inc. (NASDAQ: APYX ) is estimated to report quarterly loss at $0.21 per share on revenue of $1.96 million. • Avadel Pharmaceuticals Inc. (NASDAQ: AVDL ) is estimated to report quarterly loss at $0.10 per share on revenue of $7.37 million. • Axsome Therapeutics Inc. (NASDAQ: AXSM ) is estimated to report earnings for its second quarter. • Liberty Braves Group Inc. (NASDAQ: BATRK ) is estimated to report earnings for its second quarter. • Biohaven Pharmaceutical Inc. (NYSE: BHVN ) is expected to report earnings for its second quarter. • Black Knight Inc. (NYSE: BKI ) is expected to report quarterly earnings at $0.47 per share on revenue of $290.66 million. • Bluerock Residential Growth REIT, Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ゼリス・ファ―マシュ―ティカルズ XERS Xeris Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)